

Geronmetrics: Leading the Next Generation of Discovery in Aging

Karen Bandeen-Roche, Ph.D.
Departments of Biostatistics, Medicine & Nursing
Johns Hopkins University

**Gerontology Brown Bag
Miami University
December 8, 2005**

Acknowledgments

- Hopkins Colleagues
Linda Fried, Ron Brookmeyer, Yi Huang,
Jeremy Walston, Qian-Li Xue
- Colleagues outside of Hopkins
Luigi Ferrucci, Don Ingram, Richard Miller
- Funding / Institutional Support
Johns Hopkins Older Americans Independence
Center, National Institute on Aging, Alliance
for Aging Research


Introduction

Whither “geronmetrics”?

- “Measurement of constructs in aging”
 - a.k.a.: econometrics, psychometrics, **biometrics**
 - e.g.: generalized inflammation; frailty; aging
- Boring, no?
 - **NO!**
- Rather: essential to
 - Sensitivity for genetic, other discovery
 - Theory operationalization, testing
 - Specificity for genetic, other discovery
 - **Correctly targeted, evaluated interventions**

Introduction

The Frailty Construct



Fried et al., J Gerontol 56:M146-56; Bandeen-Roche et al., J Gerontol, in press

Frailty: Scientific Aims

- Validate theory that frailty is:
 - More than a marker of disease
 - More than severe disability
 - A ***syndrome***: more than component parts
- Specific Aims
 - Drilling down: from phenotype to etiology
 - Specificity: a measure tied explicitly to dysregulation
 - Product: a refined summary variable

Outline


- Big picture: Biological aging
 - Four measurement paradigms
 - Partner: Alliance on Aging Research
- Application: Pro-inflammation
 - Component underlying frailty
 - Data: InCHIANTI (*Ferrucci et al., JAGS, 48:1618-25*)
- Etiological mechanisms: A few words

Biological Aging

- Hypothesis: Individual specificity
 - Seems manifestly true... however:
 - Identifiable? Less manifestly true?
 - Animal evidence: e.g. dog breeds
- Goal: Surrogate measurement via biomarkers
 - Alliance for Aging Research Initiative
 - Import: Research, interventions to slow aging
- Previous attempts: disappointing
- Guiding Principles
 - **Multivariate** validation
 - **Differentiation** from disease, other cofactors of aging

Identifying Biological Aging

Paradigm #1: Age-Relatedness




- Challenges

- Age \neq aging
- Selection in studies: healthiest
- Methodological: Multiple outcomes
- Choice of measures: reliable; content-valid

Identifying Biological Aging Paradigm #2: Predictive Validity

- “Aging” = combination of aging-related variables that “best” predicts outcome(s)




- Methods: Neural networks, regression trees, logic regression, etc.

Identifying Biological Aging

Paradigm #2: Challenges

- Distinction between “aging-related variables” and “outcomes of aging”
- Agreement on “outcomes of aging”
- Methodological
 - Cross-validation
 - Multiple outcomes

Identifying Biological Aging Paradigm #3: Latent Variables



Identifying Biological Aging

Paradigm #3: Challenges

- Computing “measures” from model
 - Option 1: “Average” in domains (e.g. principal components)
 - Option 2: Prediction “from” model
- Impact of modeling assumptions
 - “local independence” (homogeneity)
 - “model fit” \neq “unique discovery”


Identifying Biological Aging

Paradigm #4: Combinations

- Compromises between methods
 - Geek speak: penalization
 - Plainer: weighting for emphasis
- Example: Latent variable model with fit weighted to emphasize age-relatedness of “aging” (“D”)
- Nice science + statistics problem

Application: Pro-Inflammation

- Central role: cellular repair
- A hypothesis: dysregulation key in adverse aging
 - Muscle wasting (*Ferrucci et al., JAGS 50:1947-54;*
Cappola et al, J Clin Endocrinol Metab 88:2019-25)
 - Receptor inhibition: erythropoetin production / anemia (*Ershler, JAGS 51:S18-21*)




Difficult to measure. IL-1RA = proxy

Study: In CHIANTI

- **Aim**
 - Causes of decline in walking ability
- **Brief design**
 - Random sample ≥ 65 years (n=1270)
 - Enrichment for oldest-old, younger ages
 - Participation: $> 90\%$ in the primary sample
- **Data**
 - Home interview, blood draw, physical exam
 - So far: Two evaluations

Conceptual framework




Statistical methodology: SEM with latent variables (AMOS)

Observed variables

- Inflammation – 5 cytokines
 - *IL-6, CRP, TNF- α , IL-1RA, IL-18*
- Mobility functioning – Z-score average
 - *Usual & rapid speed; muscle power; range of motion; neurological intactness*
- Frailty: Fried et al., 2001 criteria
 - Exhaustion; grip strength; physical activity; walking speed; weight loss
 - Continuously measured versions
- Analyses accounting for: *age, gender*

Results


- LV method: measured = physiology + noise
 - Multivariate normal underlying variables, errors
 - Conditional independence of errors



Is there Value Added? In CHIANTI findings

- *YES!*
- Independent of age, sex, smoking, diseases:
Up-regulation associated with
 - *Worse mobility* functioning [*~ -.1 effect size*]
 - *Heightened frailty* prevalence [*by ~ 30%*]
- “Up-regulation” is specific, sensitive
 - No individual cytokine adds to prediction
 - Up-regulation affords superior prediction over individual cytokines

More on Specificity




Etiological Mechanisms

- Holy grail?: What causes adverse aging?
 - Experimental data on humans: hard to come by
 - Observational, longitudinal data: central
- Cohort studies on aging abound
 - EPESE; CHS; HRS/ALIVE
 - Women's Health and Aging Study (WHAS)
 - In CHIANTI
- How to utilize existing data to most nearly address causality?

Causal Models

- Three queries (*Pearl, 2000*)
 - Predictions
 - “Probabilistic causality” (*von Suppes, 1970*)
 - Is bad function probable among the inflamed?
 - Interventions / Experiments (*Bollen, 1989*)
 - Association, temporality, isolation
 - Does bad function follow inflammation?
 - Counterfactual
 - Does one’s function change if inflamed vs. not?
 - *Neyman, 1923; Stalnaker, 1968; Lewis, 1973; Rubin, 1974; Robins 1986; Holland 1988*


Toward “causal” inferences?




- Propensity scoring (*Rosenbaum/Rubin, 1983; Imai/Van Dyk, 2004*)
- My work: Implementation amid latent variables
- Whichever causal method: Assumptions

Propensity Score Model

- $I_1 \sim$ age, cancer hx, CVD hx
- $I_2 \sim$ age, gender, diabetes hx, smoking hx



Inflammation Effects (Summary 2)



raw adjusted PS-full PS-red. diab/sm young cancer

Recap

- Presented: Frameworks for measurement
 - of complex geriatric health states
 - that incorporating biological knowledge
 - integrating causal inference methods
- Demonstration: Inflammation and adverse outcomes in In CHIANTI

Future Goals

- Extension across biological systems
- Cross-validation across populations
- Assessment of extent to which
“associations”  “mechanisms”
- Translation into interventions

Research needed

- Theory elicitation, incorporation
- Methods for synthesizing inferences across multiple data sets
- Best methods for deriving measures “M” for subsequent usage
- Surrogacy : “M” strongly relates to aging (A); treatment independent of M given A

Implications

- Refined understanding of aging states and their measurement
 - Integrating systems biology
 - Increasing sensitivity, specificity
- Heightened accuracy, precision for
 - Delineating etiology
 - Developing and targeting interventions